Coming Soon
Find comprehensive information on Amphetamine Abuse, including diagnostic criteria, clinical documentation guidelines, and medical coding for Amphetamine Use Disorder and Stimulant Abuse. Learn about signs, symptoms, treatment options, and best practices for healthcare professionals dealing with amphetamine addiction and substance use disorders. This resource provides valuable insights for accurate and efficient medical coding and documentation related to amphetamine-related diagnoses.
Also known as
Amphetamine use, abuse and dependence
Covers various amphetamine-related disorders, including abuse.
Other stimulant use, abuse and dependence
Includes abuse of stimulants not separately classified, like other amphetamines.
Cocaine use, abuse and dependence
While not amphetamine, it's a related stimulant abuse diagnosis.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is the amphetamine use causing clinically significant impairment or distress?
When to use each related code
| Description |
|---|
| Amphetamine abuse leading to significant impairment or distress. |
| Stimulant use causing intoxication, withdrawal, or other mental/physical problems. |
| Substance use disorder not otherwise specified. |
Coding requires specifying the type of amphetamine (e.g., dextroamphetamine, methamphetamine) for accurate billing and data analysis.
Distinguishing between abuse and dependence is crucial for proper coding (e.g., F15.10 vs. F15.20) and impacts severity reflection.
Documenting and coding co-occurring mental health disorders (e.g., anxiety, depression) is essential for complete patient representation and appropriate care.
Q: What are the most effective evidence-based interventions for amphetamine use disorder in adolescents, considering both pharmacological and non-pharmacological approaches?
A: While no FDA-approved medications currently exist for treating amphetamine use disorder (AUD) specifically in adolescents, several evidence-based non-pharmacological interventions demonstrate efficacy. Contingency management (CM), utilizing positive reinforcement for abstinence, is a well-established approach. Cognitive behavioral therapy (CBT) helps adolescents identify triggers, develop coping mechanisms, and modify drug-related cognitions. Family-based interventions, such as multidimensional family therapy (MDFT) or brief strategic family therapy (BSFT), address family dynamics and communication patterns contributing to substance use. Motivational interviewing (MI) can increase readiness to change and engagement in treatment. For co-occurring mental health conditions, integrated treatment models addressing both AUD and other disorders are crucial. Explore how combining CBT with family therapy can improve outcomes in adolescent amphetamine abuse treatment. Consider implementing CM alongside therapy to enhance abstinence rates. Further research is needed to determine the effectiveness of medications like naltrexone or bupropion, currently utilized in adult AUD, for adolescent populations.
Q: How can clinicians differentiate amphetamine intoxication from other stimulant-induced presentations (e.g., cocaine, synthetic cathinones) and psychiatric disorders (e.g., bipolar mania, schizophrenia) during the initial assessment?
A: Differentiating amphetamine intoxication from other stimulant-induced states and primary psychiatric disorders requires careful consideration of clinical presentation, history, and toxicological testing. While all stimulants can cause agitation, elevated mood, and tachycardia, some distinguishing features may exist. Amphetamine intoxication may present with more prominent stereotyped behaviors (e.g., repetitive movements, picking) and paranoia compared to cocaine. Synthetic cathinones can produce more pronounced sympathomimetic effects and prolonged duration of action. Distinguishing from bipolar mania requires assessing the longitudinal course; mania typically involves episodic mood elevation interspersed with periods of euthymia or depression, unlike the acute onset seen in intoxication. Similarly, psychotic symptoms in amphetamine intoxication are usually transient and resolve upon drug clearance, whereas schizophrenia involves persistent and pervasive psychotic features. Comprehensive history, including substance use patterns and psychiatric history, helps in differentiating these conditions. Urine drug screening confirms the presence of amphetamines, but cannot always distinguish between specific stimulants. Consider implementing standardized screening tools for substance use and co-occurring disorders. Learn more about specific symptoms and timelines associated with various stimulant intoxications to improve diagnostic accuracy.
Patient presents with symptoms consistent with amphetamine abuse, also known as stimulant abuse or amphetamine use disorder. The patient reports a pattern of amphetamine use leading to clinically significant impairment or distress, as manifested by continued use despite negative consequences. Symptoms include increased heart rate, elevated blood pressure, dilated pupils, insomnia, restlessness, and agitation. The patient acknowledges cravings for amphetamines and difficulty controlling amphetamine use. The patient's social and occupational functioning has been negatively impacted by their amphetamine use, as evidenced by job loss and strained family relationships. Differential diagnoses considered include other substance use disorders, anxiety disorders, and mood disorders. Assessment includes a thorough substance use history, mental status examination, and laboratory testing to assess for amphetamine toxicity and rule out other medical conditions. Treatment plan includes referral to addiction medicine specialist for further evaluation and management, consideration for cognitive behavioral therapy (CBT) and motivational interviewing, and exploration of pharmacotherapy options for amphetamine dependence. ICD-10 code F15.10 will be applied for amphetamine abuse, unspecified. Patient education provided regarding the risks and consequences of amphetamine use and the importance of adherence to the treatment plan. Follow-up appointment scheduled to monitor progress and adjust treatment as needed.